Nanoviricides updates at-the-market offering cap to $2.37 million

Nanoviricides, Inc. filed Amendment No. 2 to its prospectus supplement on October 21, 2026, dated as Amendment No. 2 dated October 21, 2026, to a prospectus supplement originally dated July 17, 2026, under Registration No. 333-296550.¹

The amendment covers the company's at-the-market stock sale arrangement. It updates the maximum amount of common stock, par value $0.00001 per share, that Nanoviricides may issue and sell through D. Boral Capital LLC as sales agent or principal, under the At Market Issuance Sales Agreement dated July 17, 2026.¹

The company's stock trades on the New York Stock Exchange under the ticker NNVC, according to the filing. As of October 19, 2026, the aggregate market value of the company's common stock held by non-affiliates was $43,161,651, calculated using 25,539,439 shares outstanding held by non-affiliates as of that date and a $1.69 closing price from September 21, 2026.¹

The company said it had sold approximately $12,012,443 of common stock under the relevant SEC instruction during the trailing 12 calendar months ending on the filing date.¹

Under SEC rules governing smaller issuers, Nanoviricides is barred from selling more than one-third of its public float in primary offerings on Form S-3 within any 12-calendar month period, so long as its public float stays below $75 million.¹

As a result of these calculations, the company said it may currently offer and sell common stock through or to the Agent for an aggregate offering price of up to $2,374,774 under the amended prospectus supplement.¹

Nanoviricides stated that if its public float rises enough to permit additional sales under the agreement, it will file another amendment before conducting further sales.¹